118
Participants
Start Date
October 28, 2021
Primary Completion Date
August 23, 2022
Study Completion Date
August 23, 2022
Cabotegravir Injectable Suspension
CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
Rilpivirine Injectable Suspension
RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
GSK Investigational Site, New York
GSK Investigational Site, Berlin
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Santiago de Compostela
GSK Investigational Site, Milan
GSK Investigational Site, Hamburg
GSK Investigational Site, Lynchburg
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Málaga
GSK Investigational Site, Hanover
GSK Investigational Site, Macon
GSK Investigational Site, Vero Beach
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Sarasota
GSK Investigational Site, Ft. Pierce
GSK Investigational Site, Vigo
GSK Investigational Site, Seville
GSK Investigational Site, Valencia
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Omaha
GSK Investigational Site, Bakersfield
GSK Investigational Site, Ciudad de Buenos Aires
GSK Investigational Site, Rosario
GSK Investigational Site, Ottawa
GSK Investigational Site, Regina
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Elche (Alicante)
GSK Investigational Site, Gothenburg
GSK Investigational Site, Stockholm
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
ViiV Healthcare
INDUSTRY